ReadMax—a novel reading and scoring approach for EGFR gene copy number to predict therapeutic benefit of erlotinib treatment in EGFR wild‐type non‐small‐cell lung cancer
EGFR mutation testing is now well established as a means of selecting the optimal first‐line therapy for patients with advanced non‐small‐cell lung cancer (NSCLC). However, deciding on the correct treatment for EGFR wild‐type NSCLC remains a challenge. EGFR fluorescence in‐situ hybridization (FISH)...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
John Wiley and Sons Inc.
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939878/ |